Role of Perhexiline in Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy Clinical Trial

— RESOLVE-HCM  

Official title:

Randomised Controlled Trial of pErhexiline on regreSsion Of Left Ventricular hypErtrophy (LVH) in Patients With Symptomatic Hypertrophic CardioMyopathy (RESOLVE-HCM)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04426578
• Other study ID #: HCM2020-01
• Status: Recruiting
• Phase: Phase 2
• Start date: December 1, 2020
• Est. completion date: August 1, 2022

Study information

• Verified date: March 2021
• Source: Flinders University
• Contact: Joseph Selvanayagam
• Phone: +61882045619
• Email: joseph.selva[@]sa.gov.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart muscle condition affecting up to 1 in 200 of the general population. It results from mutations in genes encoding components of the contractile apparatus in the heart muscle cell (myocyte). These mutations result in increased energy cost of force production for the myocyte which then cumulatively causes a myocardial energy deficit. This myocardial energy deficit is then thought to lead to cardiac hypertrophy ('left ventricular hypertrophy' or LVH) in HCM.

LVH leads to impairments in heart muscle function, heart muscle oxygenation and microvascular blood flow and is the chief driver of patient symptoms in HCM. These symptoms consist of chest pain, shortness of breath, dizziness, fainting episodes or palpitations. Occasionally, the disease may cause sudden cardiac death (SCD). HCM is the most common cause of SCD in young people including competitive athletes. In addition, HCM has been found to result in significant global deterioration in health-related quality of life.

Treatment of HCM has focused on relief of symptoms by drugs such as ß-blockers which slow the heart rate and improve heart function. However, symptom relief is often incomplete and there is no evidence on the benefit of ß-blockers or related medications to reverse LVH. Perhexiline, a potent carnitine palmitoyl transferase-1 (CPT-1) inhibitor shifts myocardial metabolism to more efficient glucose utilisation and rectifies impaired myocardial energetics. It is currently used to treat angina in patients with coronary artery disease. There is some preliminary evidence that Perhexiline may aid in the improvement of symptoms in patients with HCM. However, the effect of any form of therapy on potential regression of LVH in HCM remains unexplored.

In this randomised double-blind placebo-controlled trial, the investigators will use state of the art cardiac imaging, principally advanced echocardiography and Cardiovascular Magnetic Resonance (CMR) to study the effects of perhexiline on LVH, cardiac function, and oxygenation in symptomatic patients with HCM. The investigators hypothesize that perhexiline will favourably reduce LVH and improve myocardial oxygenation by improving myocardial energetics, and that these putative morphological and functional changes can be accurately measured utilizing echocardiography and CMR. If this pilot study supports the hypothesis, then it will pave the way for a major randomised controlled trial to definitely determine the role of Perhexiline in HCM.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 1, 2022
• Est. primary completion date: August 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Left Ventricular Ejection Fraction (LVEF) =/> 55% by echocardiography or CMR during the screening period or within 6 months prior to study entry

2. Current / prior symptom(s) of HCM (New York Heart Association [NYHA] functional class II or class III, Canadian Cardiovascular Society [CCS] grade II or grade III) and requiring treatment with ß-blockers and /or non-dihydropyridine calcium antagonists and / or disopyramide for at least 30 days prior to study entry

3. Structural heart disease as evidenced by interventricular septal thickness of (= 15 mm) on echocardiography or CMR in the absence of abnormal loading conditions

4. Elevated N terminal pro-brain natriuretic peptide (NT-proBNP), >125 pg/ml

Exclusion Criteria:

1. Any prior echocardiographic or CMR measurement of LVEF <55%

2. Current acute decompensated heart failure requiring hospitalisation and / or augmented medical therapy

3. Cardiac surgery or catheter-based septal reduction therapy planned or having occurred within the past 1 year

4. Patients with a non-CMR conditional pacemaker / implantable cardioverter-defibrillator device

5. History of a known chronic liver disease, peripheral neuropathy, recurrent hypoglycemia

6. Serum bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or lactate dehydrogenase > 2.0 times upper limit of normal

7. Previous adverse reaction to perhexiline at therapeutic plasma levels of the drug

8. Concomitant use of amiodarone, ranolazine or trimetazidine

9. Life-threatening or uncontrolled dysrhythmia

10. Contraindications to CMR, gadolinium, adenosine

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Hypertrophic
• Hypertrophic Cardiomyopathy
• Hypertrophy

Intervention

Drug:
• Perhexiline
All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be "trough" in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated "slow metabolisers" and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding. Compliance will be assessed by capsule count.

Other:
• Placebo
All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be "trough" in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated "slow metabolisers" and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding. Compliance will be assessed by capsule count.

Locations

Country	Name	City	State
Australia	Flinders Medical Centre	Adelaide	South Australia

Sponsors (1)

Lead Sponsor	Collaborator
Flinders University

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Left Ventricular Hypertrophy (LVH)	Change in LVH (septal thickness) in symptomatic at 12 months following perhexiline therapy in HCM patients assessed by CMR	12 months post baseline
Secondary	Change in Left Ventricular (LV) mass	Change in left ventricular mass in symptomatic at 12 months following perhexiline therapy in HCM patients assessed by CMR	12 months post baseline
Secondary	Change in oxygen-sensitive Cardiac Magnetic Resonance	Change in oxygen-sensitive CMR in symptomatic at 12 months following perhexiline therapy in HCM patients	12 months post baseline
Secondary	Change in left ventricular diastolic function	Change in left ventricular diastolic function at 12 months following perhexiline therapy in HCM patients assessed by echocardiography	12 months post baseline
Secondary	New York Heart Association (NYHA) functional classification	Change in NYHA classification of Class I, II, III and IV at 12 months following perhexiline therapy in HCM patients	12 months post baseline
Secondary	Canadian Cardiovascular Society (CCS) functional class	Change in CCS functional classification of Grade I, II, III and IV at 12 months following perhexiline therapy in HCM patients	12 months post baseline
Secondary	Quality of life assessment	Change in physical activity domain score of Short Form 36 Health Survey Questionnaire (SF36) at 12 months following perhexiline therapy in HCM patients	12 months post baseline
Secondary	Major adverse event on heart failure related hospitalisations	HCM patients admitted with heart failure during the study period	Monitored over the 12 months period
Secondary	Major adverse event on arrhythmic events	HCM patients admitted with arrhythmic events during the study period	Monitored over the 12 months period
Secondary	Major adverse event on abnormal liver function test	HCM patients with abnormal liver function tests during the study period	Liver function tests at baseline, 1 month, 6 months and 12 months
Secondary	Major adverse event on sudden cardiac death	HCM patients with sudden cardiac death during the study period	Monitored over the 12 months period